

# Virginia L Filiaci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2693437/publications.pdf>

Version: 2024-02-01

57  
papers

6,551  
citations

145106

33  
h-index

182931

54  
g-index

58  
all docs

58  
docs citations

58  
times ranked

4065  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.	0.8	38
2	A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. <i>Gynecologic Oncology</i> , 2022, 164, 481-491.	0.6	19
3	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. <i>Gynecologic Oncology</i> , 2022, 164, 428-436.	0.6	5
4	<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3289-3300.	0.8	19
5	A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. <i>Clinical Cancer Research</i> , 2021, 27, 2734-2741.	3.2	7
6	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 113-121.	0.6	42
7	Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 27-35.	0.6	1
8	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	0.8	155
9	An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. <i>Gynecologic Oncology</i> , 2020, 158, 354-360.	0.6	17
10	Phase II evaluation of copanlisib, a selective inhibitor of PI3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). <i>Gynecologic Oncology Reports</i> , 2020, 31, 100532.	0.3	9
11	Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2020, 157, 312-322.	0.6	6
12	Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants. <i>Supportive Care in Cancer</i> , 2019, 27, 531-538.	1.0	11
13	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.	13.9	326
14	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1810-1818.	0.8	229
15	A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5500-5500.	0.8	29
16	A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 274-281.	0.6	105
17	Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: A Gynecologic Oncology Group/NRG study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5589-5589.	0.8	4
18	Disparities in health-related quality of life in women undergoing treatment for ovarian cancer: The role of individual-level and contextual social determinants.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18628-e18628.	0.8	0

#	ARTICLE	IF	CITATIONS
19	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2017, 146, 247-253.	0.6	23
20	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. <i>Gynecologic Oncology</i> , 2017, 145, 519-525.	0.6	52
21	Synuclein $\beta$ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. <i>Cancer</i> , 2017, 123, 1144-1155.	2.0	11
22	A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1313.	0.4	38
23	A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5505-5505.	0.8	58
24	Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. <i>Obstetrics and Gynecology</i> , 2016, 128, 535-542.	1.2	58
25	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016, 141, 43-48.	0.6	21
26	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015, 51, 271-281.	1.3	108
27	Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N. <i>Gynecologic Oncology</i> , 2015, 138, 24-29.	0.6	40
28	A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5500-5500.	0.8	34
29	Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5592-5592.	0.8	2
30	The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16509-e16509.	0.8	0
31	Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2014, 132, 585-592.	0.6	113
32	2A phase II study to determine the response to second curettage as initial management for persistent $\beta$ -low-risk non-metastatic gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 134, 438-439.	0.6	9
33	Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5594-5594.	0.8	2
34	Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 87-93.	0.6	23
35	Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 125, 771.	0.6	214
36	Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2011, 120, 185-188.	0.6	60

#	ARTICLE	IF	CITATIONS
37	Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 825-831.	0.8	139
38	Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2727-2731.	0.8	151
39	A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009, 112, 543-552.	0.6	208
40	An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2008, 108, 3-9.	0.6	154
41	Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 526-531.	0.8	246
42	Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2007, 106, 325-333.	0.6	146
43	The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2007, 106, 16-22.	0.6	156
44	Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia. <i>Cancer</i> , 2006, 107, 1280-1286.	2.0	38
45	Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 36-44.	0.8	839
46	Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. <i>Annals of Oncology</i> , 2004, 15, 1173-1178.	0.6	189
47	A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2004, 92, 744-751.	0.6	1,531
48	Erratum to "A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study" [Gynecol. Oncol. 92 (2004) 744-751]. <i>Gynecologic Oncology</i> , 2004, 94, 241-242.	0.6	26
49	A Phase III Trial of Surgery With or Without Adjunctive External Pelvic Radiation Therapy in Intermediate-Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study. <i>Obstetrical and Gynecological Survey</i> , 2004, 59, 516-518.	0.2	3
50	Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2003, 89, 470-474.	0.6	28
51	Goserelin Acetate as Treatment for Recurrent Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 557-560.	0.6	75
52	A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2000, 78, 212-216.	0.6	198
53	A Phase III Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2000, 79, 147-153.	0.6	248
54	DNA Content Is an Independent Prognostic Indicator in Endometrial Adenocarcinoma A Gynecologic Oncology Group Study. <i>International Journal of Gynecological Pathology</i> , 1998, 17, 312-319.	0.9	37

#	ARTICLE	IF	CITATIONS
55	Villoglandular Adenocarcinoma of the Endometrium: A Clinicopathologic Study of 61 Cases. American Journal of Surgical Pathology, 1998, 22, 1379-1385.	2.1	66
56	Secondary Cytoreductive Surgery at Second-Look Laparotomy in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology, 1997, 66, 171-178.	0.6	48
57	An Analysis of Cell Type in Patients with Surgically Staged Stage IB Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecologic Oncology, 1996, 63, 304-311.	0.6	137